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Abstract 
Background: 
Inhibitor development represents the most serious side effect of haemophilia treatment. Any 
difference in risk of inhibitor formation depending on the product used might be of clinical relevance.  
Objective:  
To assess inhibitor development according to clotting factor concentrate in severe haemophilia A and 
B. 
Methods:  
The European Haemophilia Safety Surveillance (EUHASS) was set up as a study monitoring adverse 
events overall and according to concentrate. 
Since October 2008, inhibitors were reported at least quarterly. Number of treated patients was 
reported annually, specifying the number of patients completing 50 exposure days (PUPs) without 
inhibitor development. Cumulative incidence, incidence rates and 95% Confidence Intervals (CI) were 
calculated.  
Results:  
Data from Oct 1
st
, 2008 to Dec 31
st
, 2012 were analyzed for 68 centers that validated their data. 
Inhibitors developed in 108/417 (26%; CI 22-30%) PUPs with severe haemophilia A and 5/72 (7%; CI 2-
16) PUPs with severe haemophilia B. For Previously Treated Patients (PTPs), 26 inhibitors developed in 
17,667 treatment years (0.15/100 treatment years (CI 0.10-0.22)) for severe haemophilia A and 1/2836 
(0.04/100;(CI 0.00-0.20) for severe haemophilia B. Differences between plasma-derived and 
recombinant concentrates, or among the different recombinant FVIII concentrates were investigated.  
Conclusion:  
While confirming the expected rates of inhibitors in PUPs and PTPs, no class or brand related 
differences were observed. 
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Introduction: 
Haemophilia A and B are rare diseases affecting 1 in 10,000 and 1 in 50,000 individuals respectively (1). 
Since the development of cryoprecipitate in the 1960s(2) and clotting factor concentrates in the 1970s, 
a very effective replacement therapy is available for treatment of these patients. Overall treatment 
availability, together with the development of home-treatment and prophylaxis, has dramatically 
improved outcome and quality of life of haemophilia patients (3,4). Unfortunately, plasma-derived 
concentrates manufactured before the mid-1980s were contaminated with Hepatitis C and HIV virus, 
infecting many of the recipients. Since then, while viral inactivation has been implemented in the 
manufacturing of plasma derived concentrates (1), recombinant concentrates, virtually devoid of any 
transfusion infection risk, have been developed and became widely used in several European 
countries. Nowadays, the development of anti-factor VIII/IX inhibitors is the most frequent side effect 
of haemophilia treatment. This is most likely to occur during the initial 50 exposure days (EDs) to 
concentrate (in 25-32% of patients with haemophilia A and 5-10% of patients with haemophilia B (5-7)) 
but can also occur, in previously treated patients (PTPs), though much more rarely (1-5 per 1000 
treatment years)(8). Treatment and prevention of bleeding in patients with inhibitors and inhibitor-
eradication are the biggest challenges in haemophilia care today, making inhibitor prevention an 
important target.  
In addition to endogenous risk factors, such as FVIII gene mutation, treatment related factors like 
intensive treatment are also important. In this context, many hypotheses have been proposed about 
the potential role of FVIII concentrate type in inhibitor development. Some have suggested that 
plasma derived FVIII concentrates are associated with less inhibitor development (9), others suggested 
that this finding could be due to confounding by study characteristics (10). Therefore, a randomized 
trial was initiated to address the issue in previously untreated patients (PUPs) (11).  
Recently, the large multicentre observational study (RODIN) originating from the PedNet registry, 
reported that second generation recombinant FVIII concentrates were associated with more frequent 
inhibitor development in PUPs with severe haemophilia A (12). In addition, it has been suggested that 
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a B-domain deleted product (BDD rec FVIII) was associated with a higher inhibitor risk in previously 
treated patients (PTPs), a result which was not confirmed in a subsequent meta-analysis (8,13).  
Early identification of risks of transmission of blood borne pathogens or inhibitor development are 
best addressed by prospective surveillance strategies or large cohort studies (12,14). Studies carried 
out by manufacturers as part of their licensing application typically involve highly selected small 
cohorts of usually less than 100 patients with a limited follow up. The European Haemophilia Safety 
Surveillance (EUHASS) commenced in 2008 to monitor treatment safety according to clotting factor 
concentrate brand and class in a large number of sentinel centres in Europe (15). 
The present study reports the first four-year results of monitoring for inhibitor development in 
haemophilia in the EUHASS study. 
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Methods: 
The design of the EUHASS study has already been reported (15,16). EUHASS is an international 
multicenter pharmacosurveillance system covering an open population. Briefly, data collection started 
on October 1st in 2008, or subsequent years for centres that joined EUHASS later.  Subsequently, 
centres provided reports on all new inhibitors diagnosed at the centre every three months, using a 
secure web-based data-entry system. Inhibitors were defined as two consecutive tests above the local 
laboratory threshold; information on recovery tests was not collected, nor was central laboratory 
confirmation performed. For each patient with an inhibitor, anonymized data on age, type and severity 
of haemophilia, cumulative number of EDs to FVIII/FIX concentrate before inhibitor development (for 
each concentrate used), the date of the last negative inhibitor titre, the dates and titres of the first two 
positive inhibitor titres, the type of inhibitor test used, and the local threshold for positive inhibitor 
testing were collected. EDs were recorded up to 1000 EDs, and coded as >999 EDs for patients with 
1000 EDs or more. Only new inhibitors with positive titres on two occasions were considered. 
Data on the total number of patients at risk of inhibitor development are collected annually. The 
number of PUPs with severe haemophilia at risk for inhibitor development was established by 
collecting the number of PUPs reaching 50 EDs without developing an inhibitor in the previous year. 
These data were captured according to the concentrate used at the time of reaching 50 EDs including 
details of switching concentrate. 
For PTPs, the number of treatment-years without inhibitor development was established by collecting 
the number of PTPs without inhibitor development who continued on a concentrate, as well as the 
number of PTPs switching to this concentrate during the year of observation.  
The present analysis was based on data in patients with severe haemophilia A and B from Oct 1
st
 2008 
to Dec 31
st
 2012.  
Logical checks as well as checks for completeness of data are performed on each adverse event at the 
time of reporting. In the spring of 2013, all centres were asked to confirm accuracy and completeness 
of their data on adverse events and patients at risk entered up to Dec 31
st
 2012. Logical checks for 
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reported inhibitors included checking consistency of data, details provided in comments, age of 
patient, and check of inhibitor titre according to the local reference standard. Logical checks for non 
inhibitor patients included checks for consistency with other summary tables (e.g. total number of 
patients treated according to diagnosis with data on number of patients treated according to 
concentrate), consistency over the years and distributions of patient categories (e.g. proportion with 
haemophilia B, number of PUPs reaching 50 EDs relative to the total number of severe patients). Only 
data from centres with fully checked data and resolution of all queries were included in this analysis. 
Prior to study entry all centres approached their institutional review board for approval. Regulations in 
the 26 European Countries participating vary, and for the majority of centres no formal approval was 
required. If required, approval was obtained before study participation. 
 
Statistical analysis: 
The cumulative incidence of inhibitor development in PUPs according to product was calculated by 
dividing the number of patients who developed inhibitors by the sum of the number of inhibitor 
patients and the number of patients who reached 50 ED without inhibitor development (15).. In case 
of switching concentrates, patients with inhibitors were classified according to the last concentrate 
used.  The validity of the calculation method was established by simulation studies. (16) The exact 
method (Wilson modification) was used to calculate 95% confidence intervals (CI) for data on PUPs 
(17), without adjusting for the unknown number of patients not yet reaching 50 ED, with the possible 
result that the reported confidence intervals might be larger than the actual ones. For PTPs, the 
inhibitor rate per 100 treatment-years was calculated for each concentrate. Patients who switched to 
this concentrate during the year of observation were assumed to have been using the concentrate for 
6 months. The total observation period was 4.25 years, as the fourth year of the registry covered the 
period from Oct 1
st
 2011 to Dec 31
st
 2012. Confidence intervals for data on PTPs were calculated using 
the exact method (18).  
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All analyses were performed separately according to diagnosis (haemophilia A or B) and treatment 
history (before or after completing the first 50 EDs). Within these groups, inhibitor development was 
compared according to concentrate type (plasma derived vs recombinant), origin of recombinant 
concentrate (Baby Hamster Kidney cells or Chinese Hamster Ovary cells) as well as according to the 
different concentrates.  For PUPs with severe haemophilia A, a sensitivity analysis was performed by 
excluding data collected during the first three years of EUHASS, for patients reported by centers 
participating in the RODIN study. The RODIN study included patients born up to Jan 1
st
 2010, collected 
data until May 1
st
 2011 (HM van den Berg, personal communication), and the median age at reaching 
75 ED was 26 months (6). Year 4 of EUHASS started in Oct 2011, a minimum 22 months after the last 
inclusion in RODIN, so none of the inhibitors could be duplicated and most patients reaching 50 EDs 
during this year were likely to be born after Jan 1
st
 2010. All analyses were performed using SPSS 
version 20. 
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Results 
Since the start of the EUHASS registry in 2008, the number of centres submitting data on inhibitor 
formation and number of patients at risk for PUPs increased from 40 to 60, and the number of centres 
reporting full data on PTPs increased from 49 to 74; 14 centres treat only adult patients. An overview 
of data submitted and inhibitors according to diagnosis for PUPs and PTPs is shown in Table 1. 
Failure to confirm submitted data resulted in exclusion of events and PUPs at risk from three centres 
that reported six inhibitors and 10 non-inhibitors, resulting in the inclusion of 95% of all inhibitors in 
PUPs. For PTPs, events and numbers at risk from six centres, including six inhibitors in 2290 treatment 
years, were excluded from the analysis resulting in the inclusion of 92% of centres and 82% of 
inhibitors in PTPs. Overall, centres analysed treated a median of 75 patients with severe haemophilia 
(interquartile range (IQR) 34-131; range 7-428).  
 
 
Inhibitor development in PUPs with severe haemophilia 
Characteristics of all inhibitor patients reported to EUHASS and after exclusion of those reported in the 
RODIN study, are shown in Table 2.  There were no missing data on inhibitor patients. Inhibitors 
developed very early, at a median age of 1.3 years and 13 EDs for PUPs with haemophilia A and 2.1 
years and 11 EDs for PUPs with haemophilia B. Only the first two positive inhibitor titers were reported 
to EUHASS, taken with a median interval of 13 days (IQR 6-28). Exclusion of patients reported in the 
RODIN study (i.e. in years 1-3 of EUHASS for centres participating in both studies) resulted in a 35% 
reduction of reported inhibitors in PUPs with severe haemophilia A (from 108 to 70) and in a 29% 
reduction of the observed PUP population (from 417 to 297). Characteristics of all inhibitor patients 
reported and those reported to EUHASS only were similar.  
 
Overall, 108 inhibitors were observed in 417 PUPs with severe haemophilia A  (25.9%, CI 21.8-30.4) 
and five inhibitors in 72 PUPs with severe haemophilia B (6.9% CI 2.3-15.5). Inhibitor development in 
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PUPs according to concentrate type is shown in Table 3. Product switching occurred in only 4.3% of 
PUPs:  in  2/108 inhibitor patients and in 16/309 patients without inhibitors. Inhibitor development 
was similar across plasma derived and recombinant FVIII concentrates, with 21.6% and 26.5% inhibitor 
incidence respectively, but the number of patients treated with plasma derived products was low (12% 
of all PUPS reported). 
When comparing different recombinant FVIII concentrates according to product and cell-line, only 
marginal differences in inhibitor incidences were observed, with consistent large overlaps between the 
respective confidence intervals.  
After exclusion of overlapping data from the RODIN study, the overall inhibitor development in PUPs 
with severe haemophilia A was similar at 23.2% (69/297, CI 18.6-28.6%). During these 3 years of 
overlap between the two studies, the relative risk of inhibitor development in Kogenate Bayer/Helixate 
NextGen compared to Advate in the overlapping subgroup of the sample was very similar to the HR 
observed in RODIN: 1.67 (CI 0.95-2.95), while no difference was seen in the not overlapping subgroup 
(0.95, CI 0.59 – 1.56; see Table 3 for number of events and patients at risk). Indeed, the cumulative 
incidence of inhibitors for Kogenate Bayer/Helixate NextGen in the participating RODIN centres 
appeared increased at 44.7% (CI 28.6-61.7) compared to 25.7 % (CI 18.3-34.8) in the remaining 
EUHASS centres (statistical significance not reached). Another difference between centres 
participating in RODIN and the remaining centres was the distribution of recFVIII concentrates. During 
the four years of observation, centres participating in RODIN used significantly more Advate (49.7% (CI 
41.7-57.7) vs 30.0% (CI 23.8-36.7)) and slightly less Kogenate Bayer/Helixate NextGen (34.0% (CI 26.6-
41.9) vs 43% (CI 36.2-50.0)) than those who did not participate in RODIN.  
 
Only 11 inhibitors were observed in 51 PUPs treated with nine different plasma derived FVIII 
concentrates. None of inhibitor patients switched products, and 2/40 (5%) patients without inhibitor 
development switched products before reaching 50 EDs. Details on inhibitor development in PUPs 
with severe haemophilia A and B according to plasma derived concentrates are shown in Appendix A. 
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Inhibitor development in PTPs with severe haemophilia  
Characteristics of inhibitors in patients with severe haemophilia occurring after the 50
th
 ED are shown 
in Table 4, again there were no missing data. Inhibitors in PTPs with severe haemophilia A developed 
at a median age of 25 years and 294 EDs (IQR 95- >1000). Some of these inhibitors occurred quite 
early: 11/26 PTPs developed their inhibitor between 50 and 150 EDs, including five of these eleven 
‘early’ inhibitors developing before the age of five years. Median first inhibitor titre was 4.6 BU, with 
only 54% of patients presenting with high titre inhibitors in the first two measurements. In PTPs with 
severe haemophilia B, only one inhibitor was diagnosed at age 1.9 years after 60 EDs.  
Inhibitor development according to concentrate type for PTPs is shown in Table 5. For PTPs with 
severe haemophilia A, 26 inhibitors were observed in 17667 treatment years, resulting in an overall 
inhibitor rate of 0.15/100 treatment years (CI 0.10-0.22). When comparing plasma derived and 
recombinant FVIII concentrates, as well as different FVIII concentrate groups and individual 
recombinant concentrates, all inhibitor rates were similar with overlapping 95% confidence intervals. 
The only exception was ReFacto, represented by only 209 treatment years, which showed a higher 
inhibitor rate. Notably, the inhibitor rate reported for ReFacto was significantly higher than the 
inhibitor rate reported for its newer version ReFacto AF, represented by 2338 treatment years. 
For PTPs with severe haemophilia B, only one inhibitor was observed in a total of 2836 treatment 
years, resulting in an inhibitor rate of 0.04/100 treatment years (CI 0.001-0.20). Due to these low 
numbers, it is impossible to reliably compare inhibitor rates between different concentrate types or 
individual FIX concentrates. Details on different plasma derived FVIII and FIX concentrates are shown 
in Appendix B. 
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Discussion: 
Main findings 
With data on 489 PUPs with severe haemophilia and 20,503 treatment years in PTPs with severe 
haemophilia, the present study reports on one of the largest dataset collected following a pre-
specified protocol to date. 
The cumulative incidence of inhibitors in PUPs with severe haemophilia A was 25.9% (CI 21.8-30.4) and 
6.9% (CI 2.3-15.5) in PUPs with severe haemophilia B. Inhibitor development was similar across 
different FVIII concentrates. Inhibitor rates in PTPs with severe haemophilia A were 0.15/100 
treatment years (CI 0.10- 0.22) and for haemophilia B 0.04/ 100 treatment years (CI 0.001-0.20). 
Patient numbers were too low to compare different FIX concentrates. 
 
Study design 
An important strength of the present study is the homogenous data collection following a prespecified 
protocol from a large number of centres throughout Europe, including centres of different size and 
countries using different treatment strategies. This variability increases the generalizability of the 
results and is in sharp contrast with national studies with more homogeneous treatment strategies, 
and international studies predominantly including large centres (5,12,19). If one of the concentrates is 
associated with a true risk of increased inhibitor development, this effect should be observed 
independent of the treatment strategy used, provided a sufficient number of patient and events is 
observed. The present study is the largest attempt to date of prospectively assembling a large sample 
of non-selected patients treated in parallel with different concentrates over the same period of time 
and in several centres , which is an important advantage in comparison to single-concentrate PUP-
studies conducted by manufacturers. Due to the need for inclusion before the first exposure, these 
studies can almost exclusively include patients with a known family history of haemophilia, and are 
expected to include more patients with a negative family history of inhibitors. 
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The validity of the results of EUHASS is dependent on a constant use of the concentrates involved (15). 
The distribution of concentrates used remained stable across the four years of observation 
(supplemental data) and the validity of the results are confirmed by the observation of a slightly 
increased inhibitor risk for PUPs treated with Kogenate Bayer/Helixate NextGen in the data 
overlapping with RODIN. Weaknesses of the present study concern the level of detail of the data 
collected and the confirmation that all patients were included. Indeed, as in most 
pharmacosurveillance systems, non-differential misclassification bias could have take place, reducing 
the power to detect a difference where a difference was true. In fact, EUHASS was built with the main 
aim of accruing a large population sample, reason for which it was not possible to plan and perform 
source data monitoring (including confirmation that all patients were included), collect data on 
confounding factors or perform central testing of inhibitors. In this case, data control other than 
consistency checks was not included in the original protocol. This was acknowledged and corrected 
during the project: all reports of side effects are being checked for inconsistencies, and all centres 
were asked to review their data and answer queries for the present analysis. Centres were asked to 
report all inhibitors diagnosed, and all patients treated according to diagnosis and concentrate. The 
inclusion of all patients treated was checked by comparison with data on previous and subsequent 
years reported by the centre. Most centres answered our queries, resulting in inclusion of 95% of 
inhibitors reported for PUPs, and 82% of inhibitors reported in PTPs. Monitoring of source data and 
consistency checks are performed in the PedNet registry (12), but the United Kingdom Haemophilia 
Centre Doctors’ Organisation (UKHCDO) registry applies consistency checks only (G. Dolan, personal 
communication).   
The risk of misclassification of inhibitor development according to concentrate due to product 
switching is considered very low as only 4.3% of PUPs reported concentrate switches. 
In general, the power of studies in PUPs with severe haemophilia is limited by patient numbers. After 
four years, EUHASS was powered to detect an absolute increase of 12% in the cumulative incidence of 
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inhibitors compared to a baseline of 24% in PUPs treated with Advate (post-hoc calculation, one sided 
alpha 0.05, power 0.80). 
 
Comparison with other studies  
In EUHASS, the cumulative incidence of inhibitors in PUPs with severe haemophilia A was 25.9% (CI 
21.8-30.4), which is similar to data from large cohorts from Italy (151/565: 27%)(20), the European 
CANAL study (87/377: 24%)(5), and the RODIN study reporting 32.4% (CI 28.5-36.3%) inhibitors in 574 
PUPs with severe A. Although the overlap between EUHASS and the RODIN study could be 
approximated, it was impossible to exclude overlapping data at patient level for several reasons: first, 
date of birth was unavailable in EUHASS; second, RODIN followed patients until 75 and EUHASS until 
50 EDs; third, the analysis was different: RODIN applied survival analysis and expressed treatment as 
exposure days (calculating Hazard Ratios), while EUHASS collected data at reaching 50 EDs or inhibitor 
development only and did not consider time in the analysis (calculating cumulative incidences and 
relative risks); finally, the EUHASS study did not collect information on other risk factors for inhibitor 
development and could therefore not perform adjusted analyses. Central testing for inhibitors was not 
performed in either study. Despite the differences in methods, the proportion of high titer inhibitors 
was similar: 69% in RODIN and 63% in EUHASS. However, the increased risk of inhibitor development 
in patients treated with Kogenate Bayer/Helixate NextGen in the RODIN study (unadjusted Hazard 
Ratio 1.37 (CI 0.93-2.01) adjusted Hazard Ratio 1.60 (CI 1.08-2.37) (12)) was much less pronounced in 
EUHASS at 30.8% vs 26.2% (relative risk 1.17 (CI 0.81-1.70); odds ratio 1.25 (CI 0.75-2.09), and 
disappeared when excluding the 120 patients who were likely reported in both studies (25.7% vs 
25.9%, relative risk 0.96, CI 0.59-1.56).  
So far, the EUHASS data do not provide an explanation for the discrepancy with RODIN findings. As a 
consequence of the attempt to enrol all eligible patients in all participating centres, it is unlikely that 
the failure to confirm RODIN findings is explained by patient characteristics. Differences at centre 
level, especially different distribution of recombinant FVIII concentrates used in the centres 
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participating in RODIN compared to the other centres and differences in clinical management may play 
a role, but this can not be studied as details on treatment and other risk factors for inhibitor 
development were not collected in EUHASS. Unfortunately, the patient numbers were still too low to 
compare inhibitor development at centre level. In theory, patients with an increased inhibitor risk may 
have been prescribed Kogenate Bayer/Helixate NextGen following the publication of a very low 
inhibitor risk of 15% on Kogenate Bayer in 2005 (21). To explain the discrepancy with RODIN however, 
this selection bias must have occurred in the RODIN centres only.  
The results of the present study cannot be directly compared with those of two recent meta-analyses 
of studies reporting on inhibitor development in PUPs with severe haemophilia A, mainly because all of 
them only reported indirect comparisons (22,23). Interestingly, these meta-analyses did not observe 
differences in inhibitor development between concentrates in prospective studies, nor could they 
identify differences in study design explaining these findings. 
 
Regarding inhibitor development in PTPs with severe haemophilia A, Xi (8) analyzed 33 studies 
including 4323 patients and observed an overall inhibitor rate of 0.17/100 treatment years (CI 0.13-
0.23), which is highly compatible with the rate of 0.16/100 treatment years in EUHASS. Within the 
limitations of incomplete reporting in some studies, inhibitor rates were similar across FVIII 
concentrates. Similarly, Kempton et al reported an inhibitor rate of 0.23/100 person years in PTPs with 
severe haemophilia A (24), with similar inhibitor development across FVIII concentrates. All brands and 
generations of recombinant factor VIII presented overlapping rates in EUHASS, with the exception of 
Refacto in PTPs, with four inhibitors in 209 treatment years. Although Refacto has previously been 
associated with an increased inhibitor rate (13), the present finding in EUHASS needs to be interpreted 
with caution as it is based on a very limited number of treatment years, and was observed in PTPs 
only.  
In a report on 2528 British patients with severe haemophilia A, Hay reported on inhibitor development 
according to age, including both PUPs and PTPs. Over a period of 20 years, 51% of inhibitors occurred 
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after the age of 5 years. In these patients, the inhibitor rate was 160/26447 treatment years (0.60/100 
years, CI 0.52-0.71), which is significantly higher than the inhibitor rate reported in PTPs in the current 
study (14). Moreover, inhibitors developed much earlier in EUHASS: in 4.25 years of follow-up, 98% of 
inhibitors in PUPs, and 23% of all inhibitors in PTPs were detected before the age of 5 years. Further 
comparisons are needed to explain this discrepancy.  
A striking observation in EUHASS is that 11/26 inhibitors in PTPs with haemophilia A developed 
between 50 and 150 EDs, including five of these eleven ‘early’ inhibitors developing before the age of 
five years. Unfortunately, denominator data are for patients reaching 150 EDs are unavailable and the 
exact inhibitor rate up to 150 EDs cannot be estimated. Overall, 81% of all FVIII inhibitors developed 
before 50 EDs, and only 8% between 51 and 150 EDs. These data are insufficient to change the current 
observation period for inhibitor development in PUPs, but they suggest that regular inhibitor testing 
should be continued after reaching 50 EDs.  
Data on inhibitor development in patients with haemophilia B are very scant. From the American 
Universal Data Collection project, Peutz reported a prevalence of 67/1367 (4.9%) in severe 
haemophilia B patients, without considering differences across concentrates (25).  
 
Clinical relevance 
The issue of potentially increased inhibitor development in PUPs on Kogenate Bayer/Helixate NextGen 
remains unresolved. The data generated from this study suggest that all products available can be 
used in PUPs and PTPs with severe haemophilia A, since no differences large enough to be of clinical 
and statistical relevance were seen. If a concentrate is associated with increased inhibitor 
development, this should be observed independent of other risk factors. The present study was only 
powered to detect a 50% increase in inhibitor risk: from 24% to 36%. To detect an increase from 24% 
to 31, 500 PUPs on Kogenate Bayer/Helixate NextGen and 1000 PUPs on other concentrates are 
needed (alpha error 0.05 and power 80%). Multivariate analyses adjusting for other risk factors of 
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inhibitor development would have more power to detect small differences and would further increase 
our confidence in the absence of a difference.  
Currently, the UKHCDO and the French Coag registries (www.francecoag.org) are also analysing the 
effects of different recombinant FVIII concentrates on inhibitor development in PUPs. Combining data 
from different studies may be used to achieve sufficient data to detect smaller differences, but great 
care should be taken to avoid double reporting of single patients due to overlaps between databases. 
Combining data with additional studies may soon be possible: since 2012 Canada is running the CHESS 
registry based on the EUHASS design (http://www.ahcdc.ca/index.php/national-studies/chess), and a 
similar system open to other countries is currently being developed. The American Universal Data 
Collection system has been in place since 1998
 
and is expected to generate information too (26). Until 
then, we are not in the position to provide treatment recommendations but clinicians need to make 
decision based on all the available published evidence. Our data suggest that the issue is not 
definitively settled and there is uncertainty. 
 
 
Conclusion: 
The cumulative incidence of inhibitors in PUPs with severe haemophilia A was 25.9%, and 6.9% in PUPs 
with severe haemophilia B. Inhibitor rates in PTPs with severe haemophilia A were 0.15/100 treatment 
years, and 0.04/ 100 treatment years for severe haemophilia B. Non-adjusted inhibitor rates were 
similar across currently available FVIII and FIX concentrates for both PUPs and PTPs. 
 
18 
 
Authorship:  
K Fischer, M Makris, R Lassila, F Peyvandi, G Calizzani, A Gatt, T Lambert and J Windyga conceived and 
designed the study. M Makris and E Gilman secured funding and managed study procedures 
(governance and data management). M Makris, K Fischer, and E Gilman coordinated and performed 
datachecking. K Fischer planned and undertook the statistical analysis, which was independently 
repeated by A Iorio. All authors performed data interpretation. K Fischer and M Makris drafted the 
manuscript, which was completed with input from all authors. All the authors approved the final 
manuscript.  
Datacollection was performed by K Fischer, R Lassila, F Peyvandi, A Gatt, T Lambert, J Windyga ,A Iorio, 
M Makris and all collaborators/centers collaborating in the EUHASS project (separate list) 
 
A list of collaborators to the EUHASS project is shown in the supplementary material. 
 
The authors whish to acknowledge Professor Pier Mannuccio Mannucci for his pivotal role in the 
initiation of the EUHASS project, and  Mr Rob Hollingsworth for his role in data management and 
datachecking. 
 
 
Competing interests:. 
KF has acted as a consultant and participated in expert groups for Bayer, Baxter, Biogen, CSL Behring, 
NovoNordisk and Pfizer, has received research grants from Baxter, NovoNordisk, Pfizer, and has given  
invited educational lectures for Bayer, Baxter, NovoNordisk, and Pfizer, and has received travel 
support from Baxter and Bayer.  
FP has given invited educational lectures for Novo Nordisk, CSL Behring, Bayer and Baxter, and has 
recerved a research grant from Novo Nordisk  
 
19 
 
Al had received research grants from Bayer, Baxter and Pfizer and honoraria for advisory board 
participation and invited educational lectures from Bayer, Baxter and Pfizer. 
TL received honoraria for consultancy, advisory board participation and /or invited educational 
lectures from Baxter, Bayer, CSL Behring, and Pfizer. 
MM has acted as consultant to CSL Behring and NovoNordisk. He took part in an Advisory Panel 
organised by BPL and gave lectures for Baxter, Bayer, Biogen Idec, Biotest, Octapharma, Pfizer and 
SOBI. He has received travel support from Baxter and Bayer. 
AG, GC and EG reported no competing interests. 
RL received honoraria for advisory board participation for Novo Nordisk, Pfizer and Sanquin. FP has 
received honoraria for invited educational lectures from Novo Nordis, CSL Behring, Bayer and Baxter, 
in addition she has received research support from Novo Nordisk.  
JW has acted as a consultant and participated in expert groups for Bayer, Baxter and Novo Nordisk, 
and has received speakers fees from Bayer, Baxter, CSL Behring, Novo Nordisk, Octapharma, and 
Pfizer. 
Funding 
The EUHANET project is funded by the European Commission Health Programme through the 
Executive Agency for Health and Consumers (EAHC) (Project number 2011207) with co-financing from 
12 pharmaceutical manufacturers. The pharmaceutical companies supporting this project are Baxter, 
Bayer, Biotest, BPL, CSL Behring, Grifols, Kedrion, LFB, NovoNordisk, Octapharma, Pfizer, SOBI/Biogen 
Idec. 
 
  
20 
 
 
Table 1. Data submitted according to treatment status and diagnosis 
 PUPs PTPs 
Centres included 57/60 (95%) 68/74 (92%) 
Inhibitors included 113/119 (95%) 27/33 (82%) 
 Inhibitors 
< 50 ED 
Reaching 50 ED 
without 
inhibitors 
inhibitors Treatment 
years  
Severe haemophilia A 108 309 26 17667 
Severe haemophilia B 5 67 1 2836 
PUPs: Previously Untreated Patients; PTPs: Previously Treated Patients; ED: exposure day 
 
Table 2. Characteristics of inhibitor patients in PUPs 
 All PUPs with inhibitors reported to 
EUHASS 
excluding overlap with 
RODIN study 
 haemophilia A 
median (P25-P75) 
haemophilia B 
median (P25-P75) 
haemophilia A 
median (P25-P75) 
Number 108 5 69 
Age (yrs) 1.3 (1.0-2.0) 2.1 (1.6-3.5) 1.3 (1.0-2.0) 
Nr of ED before inhibitor 
development 
13 (9-20) 11 (8-20) 12 (9-20) 
Median 1
st
 titer 3.9 (1.8-14.8) 1.0 (0.7-217) 3.3 (1.2-14.5) 
% high titer within first two 
measurements 
63% 40% 64% 
PUPs: Previously Untreated Patients;  ED: exposure day 
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Table 3. Inhibitor development in PUPs with severe haemophilia according to concentrate type 
 All PUPs reported to EUHASS  excluding overlap with RODIN study 
 
inhibitors Total 
Cumulative 
incidence 
Lower 
CI 
Upper 
CI 
 Inhibitors Total 
Cumulative 
incidence 
Lower 
CI 
Upper 
CI 
Haemophilia A 
FVIII pd 11 51 21.6% 11.3% 35.3%  8 38 21.1% 9.6% 37.3% 
FVIII rec 97 366 26.5% 22.1% 31.3%  62 259 23.9% 19.1% 29.5% 
            
recFVIII BHK 44 143 30.8% 23.3% 39.0%  27 105 25.7% 17.7% 35.2% 
recFVIII CHO 53 223 23.8% 18.3% 29.9%  35 154 22.7% 16.4% 30.2% 
            
Advate 37 141 26.2% 19.2% 34.3%  22 85 25.9% 17.0% 36.5% 
Helixate 
NexGen 
12 37 32.4% 18.0% 49.8%  11 33 33.3% 18.0% 51.8% 
Kogenate 
Bayer 
32 106 30.2% 21.7% 39.9%  16 72 22.2% 13.3% 33.6% 
Recombinate 1 24 4.2% 0.1% 21.1%  1 24 4.2% 0.1% 21.1% 
Refacto 0 6 0.0% 0.0% 45.9%  0 1 0.0% 0.0% 97.5% 
Refacto AF 15 52 28.8% 17.1% 43.1%  12 44 27.3% 15.0% 42.8% 
            
Haemophilia B 
FIX pd 3 30 10.0% 2.1% 26.5%       
FIX rec 
(Benefix) 
2 42 4.8% 0.6% 16.2% 
      
Pd:plasma derived; rec: recombinant; FVIII BHK: FVIII produced by Baby Hamster Kidney cells 
(Kogenate Bayer and Helixate Next Gen); FVIII CHO: FVIII produced by Chinese Hamster Ovary cells. 
Inhibitor development on Kogenate Bayer/Helixate NextGen compared to Advate: All study 
(44/143)/(37/141)=1.17; RODIN excluded: (27/105) /(22/85)=0.99; RODIN only (17/38)/(15/56) =1.67 
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Table 4. characteristics of inhibitor patients in PTPs according to diagnosis 
 Severe 
haemophilia A 
median (P25-P75) 
Severe  
haemophilia B 
median (P25-P75) 
Number 26 1 
Age (yrs) 25.0 (7.6-44.8) 1.9 
Nr of EDs before inhibitor 
development 
294 (95- >999) 60 
Median 1
st
 titer 4.6 (1.3-15.3) 4.0 
% high titer within first two 
measurements 
54% 0% 
PTPs: Previously Treated Patients; ED: exposure day 
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Table 5. Inhibitor development according to concentrate type for PTPs with severe haemophilia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pd:plasma derived; rec: recombinant; FVIII BHK: FVIII produced by Baby Hamster Kidney cells 
(Kogenate Bayer and Helixate Next Gen); FVIII CHO: FVIII produced by Chinese Hamster Ovary cells. 
Severe PTP 
 Inhibitors 
(N) 
Treatment  
years 
(N) 
Inhibitors 
(N/100 yrs) 
(95% CI) 
FVIII rec 19 12959 0.15   
(0.09-0.23) 
FVIII pd 7 4708 0.15   
(0.06-0.31) 
    
FVIII BHK 7 5506 0.13  
(0.05-0.26) 
FVIII CHO  12 7454 0.16 
(0.08-0.28) 
    
Advate 5 4656 0.11 
(0.03-0.25) 
Helixate NexGen 1 1987 0.05  
(0.00-0.28) 
Kogenate Bayer 6 3519 0.17 
(0.06-0.37) 
Recombinate 0 251 0.00  
(0.00-1.46) 
Refacto 4 209 1.91  
(0.52-4.82) 
Refacto AF 3 2338 0.13 
(0.03-0.37) 
    
FIX pd 0 1150 0.00  
(0.00-0.32) 
FIX rec 
(Benefix) 
1 1686 0.06 
(0.00-0.33) 
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